Top

Published in:

01-10-2010 | Review

Antiangiogenic therapy for breast cancer

Authors: Dorte Lisbet Nielsen, Michael Andersson, Jon Lykkegaard Andersen, Claus Kamby

Published in: Breast Cancer Research | Issue 5/2010

Abstract

Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria.

Harper J, Moses MA: Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006, 96: 223-268.

Schneider BP, Sledge GW: Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol. 2007, 4: 181-189. 10.1038/ncponc0740.PubMedCrossRef

Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006, 3: 24-40. 10.1038/ncponc0403.PubMedCrossRef

Ferrara N, Hillan K, Gerber H-P, Novotny W: Discovery and development of bevacizumab, an anti VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004, 3: 391-398. 10.1038/nrd1381.PubMedCrossRef

Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Nototny WF, Reiman JD, Vassel A: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003, 30 (5 Suppl 16): 117-124. 10.1053/j.seminoncol.2003.08.013.PubMedCrossRef

Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Roades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL: Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006, 12: 3124-3129. 10.1158/1078-0432.CCR-05-2603.PubMedCrossRef

Chan D, Allen H, Hu E, Reese D, Patel G, Gottlieb C, Wax A, Sosa J, Slamon D, Kabbinavar F: Phase II study of docetaxel (D) plus bevacizumab (B) in Her2 negative metastatic breast carcinoma. J Clin Oncol. 2006, 24 (June 20 Supplement): abstract 13047-

Hurvitz SA, Kabbinavar FF, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Reese D, Slamon DJ: A phase II trial of docetaxel with bevacizumab as first line therapy for Her2/neu negative metastatic breast carcinoma. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 4062-

Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kananic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC: North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Ann Oncol. 2010, 21: 269-274. 10.1093/annonc/mdp512.PubMedCrossRef

10.

Hoelzer KL, Brufsky A, Hainsworth J, Beck JT, Whorf R, Keaton M, Kroener J, Krill-Jackson E, Hu S, Bromund J: Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer. J Clin Oncol. 2009, 27 (15S): abstract 1089-

11.

Guardino AE, Chen M, Levy M, Chen M: Phase II trial with gemcitabine, paclitaxel and bevacizumab for the first line treatment of metastatic breast cancer. Cancer Res. 2009, 69 (Suppl): abstract 6089-CrossRef

12.

Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF, Mudenda B, McHenry B, Pivot X: Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol. 2009, 27 (15S): abstract 1029-

13.

Danso MA, Blum JL, Robert NJ, Krekow L, Rotche R, Smith DA, Richards P, Anderson T, Richards DA, O'Shaughnessy J: Phase II trial of weekly nabpaclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 1075-

14.

Conlin AK, Hudis CA, Bach A, Moynaha M, Lake D, Forero-Torres A, Wright G, Hackney M, Claws A, Seidman AD: Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol. 2009, 27 (15S): abstract 1006-

15.

Sledge G, Miller K, Moisa C, Gradisar W: Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol. 2007, 25 (18S): abstract 1013-

16.

Traina TA, Theodoulou M, Dugan U, Feigin K, Patil S, Geneus S, Godfrey L, Norton L, Hudis C: A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study. Cancer Res. 2009, 69 (Suppl 2): abstract 6121-CrossRef

17.

Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M: Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008, 26: 4899-4905. 10.1200/JCO.2008.17.4789.PubMedCrossRef

18.

Rochlitz C, Spirig C, Ruhstaller T, Suter T, Bühlmann M, Fehr M, Schönenberger A, Lerch S, Mayer M, Zaman K: Bevacizumab and pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer: a multicenter, single-arm phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2009, 27 (15S): abstract 1030-

19.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reiman JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005, 23: 792-799. 10.1200/JCO.2005.05.098.PubMedCrossRef

20.

Miller KD, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056/NEJMoa072113.PubMedCrossRef

21.

Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Scheeweiss A, Wardley AM, Chlistalla A, Romieu G: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010, 28: 3239-3247. 10.1200/JCO.2008.21.6457.PubMedCrossRef

22.

Robert N, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X: RIBBON-1: a randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol. 2009, 27 (15S): abstract 1005-

23.

O'Shaughnessy J, Miles D, Gray J, Dieras V, Perez EA, Zon R, Cortes J, Zhou X, Phan S, Miller K: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol. 2010, 28 (15S): abstract 1005-

24.

Brufsky A, Bondarenko IN, Smirnov V, Hurvitz SA, Perez EA, Ponovarova O, Vynnychenko I, Swamy R, Mu H, Rivera RR: RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res. 2009, 69 (Suppl): abstract 42-CrossRef

25.

Brufsky A, Rivera RR, Hurvitz SA, Bondarenko IN, Smirnov V, Valero V, Rugo HS, Swamy R, Mu H, Perez EA: Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2010, 28 (15S): abstract 1021-

26.

Falkson C, Rossman JF, Nabell L, Carpenter J, Forero A, Kim Y, Saleh M: A phase II trial investigating if bevacizumab in combination with hormone therapy reverse acquired estrogen indepence in metastatic breast cancer patients. J Clin Oncol. 2009, 27 (15S): abstract e12027-

27.

Traina TA, Rugo H, Caravelli JF, Yeh B, Panageas K, Bruckner J, Norton L, Park J, Hudis C, Dickler M: Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol. 2006, 24 (18S): abstract 3050-

28.

Rubin MS, Barton J, Shipley D, Arrowsmith E, Peacock N, Hart L, Evans J, Vasquez E, Burris HA, Yardley D: Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer. J Clin Oncol. 2009, 27 (15S): abstract 1091-

29.

Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Nothfeldt D, Lingle W, Copland J, Perez EA: N0539 Phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group trial. Cancer Res. 2009, 69 (Suppl): abstract 4096-CrossRef

30.

Hurvitz SA, Bosserman LD, Leland-Jones B, Thirwell M, Allison MK, Barstis J, Molthrop D, Quan E, Upadhyaya G, Slamon D: A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or III breast cancer. J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 562-

31.

Makhoul I, Klimberg S, Henry-Tillman R, Westbrook K, Korourian S, Siegel E, Hutchins L: Primary systemic therapy using docetaxel/cyclophosphamide/bevacizumab (TCB) followed by doxorubicin (A) in operable or locally advanced breast cancer (BC). Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 5055-

32.

Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B: Capecitabine + docetaxel + bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 4064-

33.

Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M: Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavourable prognostic features. Anticancer Drugs. 2009, 20: 197-203. 10.1097/CAD.0b013e3283264719.PubMedCrossRef

34.

Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006, 24: 769-777. 10.1200/JCO.2005.03.4645.PubMedCrossRef

35.

Lyons JA, Silverman P, Remick S, Chen H, Leeming R, Shenk R, Fu P, Dumadag L, Escuro K, Overmoyer B: Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol. 2006, 24 (18S): abstract 3049-

36.

Raefsky E, Castillo R, Lahity A, Thompson DS, Hanson S, Meng C, Knauer D, Trieu V, Desai N, Yardley DA: Phase II study of neoadjuvant bevacizumab and trastuzumab administrated with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer. J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 627-

37.

Locatelli MA, Curigliano G, Fumagalli L, Ghisini R, Mancuso P, Bertolini F, Viale G, Lunghi L, Goldhirsch A: Bevacizumab and oral chemotherapy for patients with lymphangitis breast cancer: a phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine. J Clin Oncol. 2009, 27 (15S): abstract 1031-

38.

Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M: Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer. 2008, 99: 1564-1571. 10.1038/sj.bjc.6604741.PubMedPubMedCentralCrossRef

39.

Forero-Torres A, Galleshaw J, Jones C, Percent I, Nabell L, Carpenter J, Falkson C, Krontiras H, Bland K, De Los Santos J, Saleh MN: A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 652-

40.

Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW: Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph nodepositive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 520-

41.

Hart LL, Badarinath S, Waterhouse DM, Daniel B, Raimondo D, Burris HA, Yardley DA: A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): preliminary results. J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 575-

42.

Mayer EL, Miller KD, Rugo HS, Peppercorn JM, Carey LA, Ryabin N, Winer EP, Burstein HJ: A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol. 2007, 25 (18S): abstract 561-

43.

Sanborn RE, Sandler A: The safety of bevacizumab. Expert Opin Drug Saf. 2006, 5: 289-301. 10.1517/14740338.5.2.289.PubMedCrossRef

44.

Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Loffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS: VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002, 99: 11393-11398. 10.1073/pnas.172398299.PubMedPubMedCentralCrossRef

45.

Hobday TJ, Rowland K, Dueck A, Northfelt D, Lingle W, Morton R, Fitch T, Nikcevich D, Perez EA: N0537: A North Central Cancer Group (NCCTG) phase II trial of VEGF trp in patients with metastatic breast cancer (MBC) previously treated with an anthracycline and/or a taxane. J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 164-

46.

Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, Sharp C, Shahied-Arruda L, Doshi P, Nakada MT, Anderson GM: CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cell lines. Clin Exp Metastasis. 2008, 25: 139-148. 10.1007/s10585-007-9132-4.PubMedCrossRef

47.

Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Kock M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmelit P: Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007, 131: 463-475. 10.1016/j.cell.2007.08.038.PubMedCrossRef

48.

Chow LQM, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007, 25: 884-896. 10.1200/JCO.2006.06.3602.PubMedCrossRef

49.

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD: Phase II study of sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008, 26: 1810-1816. 10.1200/JCO.2007.14.5375.PubMedCrossRef

50.

Lyandres J, Melisko M, Moasser M, Goga A, Park JW, Rugo HS: Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer. Cancer Res. 2009, 69 (Suppl 2): abstract 4119-CrossRef

51.

Gianni L, Cardoso F, Mariani G, Isaksson-Friman E, Besse-Hammer T, Vigano L, Verkh L, Rossi C, Giorgetti C, Bergh J: Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancer. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 6079-

52.

Kozloff MF, Chuang E, Roy J, Starr A, Gowland PA, Tarpey MJ, Collier M, Verk L, Miller K: A phase I study of sunitinib plus paclitaxel for first-line treatment af advanced breast cancer: preliminary results. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 6078-

53.

Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon J-L, Wynendaele W, Focan C, Degreve J, Paridaens R: SUCON trial (SUnetinib CONsolidation therapy in metastatic breast cancer): a Belgian multicenter phase II randomized trial in Her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with sunitinib after objective response to taxane chemotherapy. Cancer Res. 2009, 69 (Suppl): abstract 203-CrossRef

54.

Bergh J, Greil R, Voytko N, Makhson A, Cortes J, Lortholary A, Huang X, Giorgetti C, Kern KA, Lichinitser M: Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol. 2010, 28 (15S): abstract LBA1010-

55.

Crown J, Dieras V, Staroslawska E, Yardley DA, Davidson N, Bachelot TD, Tassell TR, Huang X, Kern KA, Romieu G: Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol. 2010, 28 (15S): abstract LBA1011-

56.

Barrios C, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Zhang K, Kern KA, Martin M: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010, 121: 121-131. 10.1007/s10549-010-0788-0.PubMedPubMedCentralCrossRef

57.

Chu TF, Rupnick M, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, van den Abbeele AD, Demetri GD, Force T, Chen MH: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007, 370: 2011-2019. 10.1016/S0140-6736(07)61865-0.PubMedPubMedCentralCrossRef

58.

Strumberg D: Preclinical and clinical development of the oral multikinase sorafenib in cancer treatment. Drugs Today (Barc). 2005, 41: 773-784. 10.1358/dot.2005.41.12.937959.CrossRef

59.

Bianchi GV, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Penña C, Lathia C, Bergamini L, Gianni L: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009, 20: 616-624. 10.1097/CAD.0b013e32832b2ea0.PubMedCrossRef

60.

Baselga J, Grupo Espanol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólido, Roché H, Costa F, Getulio JMS, Pinczowski H, Ma EC, Cabral SF, Gomez P, van Eyll B: SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafinib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res. 2009, 69 (Suppl): abstract 45-CrossRef

61.

Gradishar WJ, Kaklamani V, Prasad TS, Lokanatha D, Raina V, Bondarde S, Jain M, Schwartzberg L: A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer. Cancer Res. 2009, 69 (Suppl): abstract 44-CrossRef

62.

Sonpavde G, Hudson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007, 9: 115-119. 10.1007/s11912-007-0007-2.PubMedCrossRef

63.

Taylor SK, Chia S, Dent S, Clemons M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard K, Leighl N: A phse II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: results after completion of stage I: a trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol. 2009, 27 (15S): abstract 1133-

64.

Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60: 2178-2189.PubMed

65.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH Wadsworth PF, Bigley AL, Hennequin LF: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62: 4645-4655.PubMed

66.

Miller KD, Trigo JM, Wheeler C, Baarge A, Rowbottom J, Sledge G, Baselga J: A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2005, 11: 3369-3376. 10.1158/1078-0432.CCR-04-1923.PubMedCrossRef

67.

Boér K, Láng I, Liombart-Cussac A, Andreasson I, Vivanco GL, Sanders N, Pover GM, Murray E: Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase II study. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 6081-

68.

Rosen LS, Kurzrock R, Mulay M, van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007, 25: 2369-2376. 10.1200/JCO.2006.07.8170.PubMedCrossRef

69.

de Boer R, White S, Mainwaring P, Koczwara B, Ye Y, Sun Y-N, Parson M, Braun A, Kotasek D: Safety and pharmacokinetics of motesanib diphosphate (AMG 706) with paclitaxel or doxorubicin for the treatment of locally recurrent, unresectable or metastatic breast cancer. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 6074-

70.

Choueiri TK: Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs. 2008, 9: 658-671.PubMed

71.

Rugo HS, Stopeck A, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Soulieres D: A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol. 2007, 25 (18S): abstract 1003-

72.

Nickoloff BJ, Osborne BA, Miele L: Notch signalling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003, 22: 6598-6608. 10.1038/sj.onc.1206758.PubMedCrossRef

73.

Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS: Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced tumors. J Clin Oncol. 2009, 27: 3557-3565. 10.1200/JCO.2008.19.6683.PubMedCrossRef

74.

Fasola A, Sessa C: mTOR inhibitors in the treatment of cancer. Expert Opin. 2008, 17: 1717-1734. 10.1517/13543784.17.11.1717.

75.

Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M: Angiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006, 66: 5549-5554. 10.1158/0008-5472.CAN-05-2825.PubMedCrossRef

76.

Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ: mTOR, a novel target in breast cancer: the effect of CCI 779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001, 8: 249-258. 10.1677/erc.0.0080249.PubMedCrossRef

77.

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005, 120: 747-759. 10.1016/j.cell.2004.12.040.PubMedCrossRef

78.

Chan S, Scheulen ME, Johnston S, Mross K, Cardosa F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005, 23: 5314-5322. 10.1200/JCO.2005.66.130.PubMedCrossRef

79.

Ellard S, Clemons M, Gelmon KA, Norris B, Kennrcke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trial Group IND.163. J Clin Oncol. 2009, 27: 4536-4541. 10.1200/JCO.2008.21.3033.PubMedCrossRef

80.

O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res. 2006, 66: 1500-1508. 10.1158/0008-5472.CAN-05-2925.PubMedPubMedCentralCrossRef

81.

Moulder SL, Rivera E, Ensor J, Gonzales-Angulo A, Christofanilli M, Booser D, Giordano S, Brewster A, Hortobagyi GN, Tran H: Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC). J Clin Oncol. 2009, 27 (15S): abstract 1066-

82.

Mayer IA, Burris HA, Bendell JC, Means-Powell J, Arteaga CL, Shyr Y, Pietenpol JA: A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Cancer Res. 2009, 69 (Suppl): abstract 3093-CrossRef

83.

Carpenter JT, Roche H, Campone M, Colomer R, Jagiello-Gruszfeld A, Moore L, D'Amore M, Kong S, Boni J, Baselga J: Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2007, 23 (16S): abstract 564-

84.

Chow LWC, Sun Y, Jassem J, Baselga J, Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L: Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006, 100 (Suppl 1): abstract 6091-

85.

Macaskill EJ, Bartlett JMS, White S, Renshaw L, Campbell FM, Young O, Stumm M, Faratian D, Thomas J, Barber MD, Dixon JM: The mammalian target of rapamycin inhibitor RAD001 (everolimus) in postmenopausal women with early breast cancer: results of a phase II pre-operative trial. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 6092-

86.

Baselga J, Semiglazow V, van Dam PA, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009, 27: 2630-2637. 10.1200/JCO.2008.18.8391.PubMedCrossRef

87.

Tortora G, Ciardiello F, Gasparini G: Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol. 2008, 5: 521-530. 10.1038/ncponc1161.PubMedCrossRef

88.

Fountzilas G, Skarlos D, Wirtz RM, Dafni U, Stropp U, Pectasides D, Papakostas P, Markopoulos C, Karapanagiotis K, Polichronis A, Timotheadou E, Grimani I, Samantas E, Kosmidis P, Kalogeras KT: Prognostic value of both HER-2 and VEGF-A mRNA over-expression in primary tumors of high-risk breast cancer patients. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 6007-

89.

Hurvitz SA, Pegram MD, Lin L-S, Chan DS, Allen HJ, Dichmann RA, Hagenstad CT, Barstis J, Hermann RC, Hu EH, Moroose RL, Thomas SP, Vogel CL, Ryba N, Elashoff D, Slamon DJ: Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res. 2009, 69 (Suppl): abstract 6094-CrossRef

90.

Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey l, Norton L, Hudis CA: Phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008, 14: 7878-7883. 10.1158/1078-0432.CCR-08-0141.PubMedPubMedCentralCrossRef

91.

Dickler M, Franco S, Stopeck A, Ma W, Nulsen B, Lyandres J, Melisko M, Lahiri S, Arbushites M, Koehler M, Rugo HS: Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer. Cancer Res. 2009, 69 (Suppl 2): abstract 3133-CrossRef

92.

Blay J-Y, Lluch A, Gutierrez M, Martin MM, Kozloff MF, Prady C, Huang X, Chen C, Tassell V, Kern K, Verma S: Sunitinib (SU) in combination with trastuzumab (T) for the treatment of advanced breast cancer (ABC): activity and safety results from a phase II. Cancer Res. 2009, 69 (Suppl): abstract 201-CrossRef

93.

Dirix L, Canon J-L, Amadori D, Villa E, Aldrighetti D, Machiels J-P, Verkh L, Bouko Y, Kern K, Giorgetti C, Cardoso F: An exploratory study of sunitinib (SU) plus docetaxel (D) and trastuzumab (T) as first-line therapy for HER2+ advanced breast cancer (ABC). Cancer Res. 2009, 69 (Suppl): abstract 6088-CrossRef

94.

Slamon D, Gomez HL, Kabbinavar F, Amit O, Richie M, Pandite L, Goodman V: Randomized study of pazopanib - lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol. 2008, 26 (May 20 Suppl): abstract 1016-

95.

O'Regan R, Andre F, Campone M, Naughton M, Manlius C, Pylvaenaeinen I, Sahmoud T, Hurvitz S: RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial. Cancer Res. 2009, 69 (Suppl 2): abstract 3119-CrossRef

96.

Yardley DA, Seiler M, Ray-Coquard I, Melichar B, Hart L, Dieras V, Barve M, Melnyk A, Dorer D, Turner CD: Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter phase II trial. Cancer Res. 2009, 69 (Suppl): abstract 3091-CrossRef

97.

Mayer IA, Means-Powell J, Shyr Y, Arteaga CL: A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. Cancer Res. 2009, 69 (Suppl): abstract 3094-CrossRef

98.

Mayer EL, Dhakil S, Patel T, Sundaram S, Fabrian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJ: SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010

99.

Falchook GS, Wheler JJ, Naing A, Hong DS, Moulder SL, Piha-Paul SA, Ng CS, Jackson E, Kurzrock R: A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. J Clin Oncol. 2010, 28 (15S): abstract 2512-

100.

Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugaki K, Yamashita Y, Mori K, Fujimoto-Ouchi K: Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs. 2010, 21: 687-694.PubMed

101.

Dempke WCM, Heinemann V: Resistance to EGF-R (erb-1) and VRGF-r modulating agents. Eur J Cancer. 2009, 45: 1117-1128. 10.1016/j.ejca.2008.11.038.PubMedCrossRef

102.

Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008, 8: 592-603. 10.1038/nrc2442.PubMedPubMedCentralCrossRef

103.

Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidsen N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD: ECOG 2100: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab ECOG 2100. J Clin Oncol. 2008, 26: 4672-4678. 10.1200/JCO.2008.16.1612.PubMedPubMedCentralCrossRef

104.

Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15: 220-231. 10.1016/j.ccr.2009.01.027.PubMedPubMedCentralCrossRef

105.

Harbeck N, Chan A, ten Bokkel Huinink D, Chollet P, Fabiani C, Salvagni S, Pérez-Michel L, Scheeweiss A, Chlistalla A, Miles DW: No clinical evidence for increase in tumour malignant potential in patients with metastatic breast cancer treated with bevacizumab and docetaxel in the phase III AVADO study. Cancer Res. 2009, 69 (Suppl): abstract 6086-CrossRef

106.

Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009, 6: 327-338. 10.1038/nrclinonc.2009.63.PubMedPubMedCentralCrossRef

107.

Murukesh N, Dive C, Jayson GC: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 2010, 102: 8-18. 10.1038/sj.bjc.6605483.PubMedCrossRef

108.

Sessa C, Guibal A, Del Comte G, Rüegg C: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nat Clin Pract Oncol. 2008, 5: 378-391. 10.1038/ncponc1150.PubMedCrossRef

109.

Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C: Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol. 2009, 72: 217-238. 10.1016/j.critrevonc.2008.07.012.PubMedCrossRef

110.

Fojo T, Grady C: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009, 101: 1044-1048. 10.1093/jnci/djp177.PubMedPubMedCentralCrossRef

111.

Duda DG, Ancukiewicz M, Jain RK: Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?. J Clin Oncol. 2010, 28: 183-185. 10.1200/JCO.2009.24.8021.PubMedCrossRef

112.

McArthur HL, Rugo H, Paulson M, Rourke M, Traina T, Panageas K, Steingart R, Dang C, Fornier M, Park J, Moasser M, Melisko M, Sugarman S, Norton L, Hudis CA, Dickler MN: Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Breast Cancer Res Treat. 2007, 106 (Suppl 1): abstract 3065-

113.

Isaacs C, Wilkinson M, Liu MC, Ottaviano Y, Chung G, Warren R, Jennifer E-W, Cohen P, Smith KL, Novielli A, Castle J, Slack R: Phase II study of sorafenib with anastrozole to overcome resistance to aromatase inhibitors (AIs) in patients with hormone receptor positive (ER/PR+) AI resistant metastatic breast cancer (MBC). Cancer Res. 2009, 69 (Suppl): abstract 3090-CrossRef

Title: Antiangiogenic therapy for breast cancer
Authors: Dorte Lisbet Nielsen
Michael Andersson
Jon Lykkegaard Andersen
Claus Kamby
Publication date: 01-10-2010
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 5/2010
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2642

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Mammary stem cells and cancer: roles of Wnt signaling in plain view

A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland

Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study

Regulation of breast cancer cell motility by T-cell lymphoma invasion and metastasis-inducing protein

Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells

Role of dietary fatty acids in mammary gland development and breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer